Otonomy, Inc. Logo
Otonomy Provides Corporate Update
19 déc. 2022 16h53 HE | Otonomy, Inc.
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan...
Otonomy, Inc. Logo
Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update
10 nov. 2022 16h05 HE | Otonomy, Inc.
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported...
Otonomy, Inc. Logo
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss
13 oct. 2022 07h30 HE | Otonomy, Inc.
Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baselineLack of activity compared to 0.3 mg dose evaluated in prior studies may be due to a complex...
Otonomy, Inc. Logo
Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
01 août 2022 07h30 HE | Otonomy, Inc.
OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepointsCompany to discontinue development of OTO-313 and implement other...
Otonomy, Inc. Logo
Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
25 juil. 2022 16h05 HE | Otonomy, Inc.
Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line...
Otonomy, Inc. Logo
Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update
18 juil. 2022 07h30 HE | Otonomy, Inc.
SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
GMILogo_Vertical-Gradient.png
U.S. Compounding Pharmacies Market to hit USD 8.7 Billion by 2030, says Global Market Insights Inc.
07 juil. 2022 06h15 HE | Global Market Insights Inc.
Selbyville, Delaware, July 07, 2022 (GLOBE NEWSWIRE) -- U.S. compounding pharmacies market value is set to reach USD 8.7 billion by 2030, according to a new research report by Global Market...
Otonomy, Inc. Logo
Otonomy to Participate in the H.C. Wainwright Global Investment Conference
18 mai 2022 07h30 HE | Otonomy, Inc.
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
Otonomy, Inc. Logo
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
12 mai 2022 07h30 HE | Otonomy, Inc.
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update
09 mai 2022 16h04 HE | Otonomy, Inc.
Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected...